- Home
- LOGC vs GNFT Comparison
LOGC vs GNFT Comparison
Compare LOGC & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- GNFT
- Stock Information
- Founded
- LOGC 2010
- GNFT 1999
- Country
- LOGC United States
- GNFT France
- Employees
- LOGC N/A
- GNFT N/A
- Industry
- LOGC Catalog/Specialty Distribution
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOGC Consumer Discretionary
- GNFT Health Care
- Exchange
- LOGC Nasdaq
- GNFT Nasdaq
- Market Cap
- LOGC 175.8M
- GNFT 172.2M
- IPO Year
- LOGC 2020
- GNFT 2019
- Fundamental
- Price
- LOGC $6.87
- GNFT $3.47
- Analyst Decision
- LOGC
- GNFT Strong Buy
- Analyst Count
- LOGC 0
- GNFT 1
- Target Price
- LOGC N/A
- GNFT $13.00
- AVG Volume (30 Days)
- LOGC 208.4K
- GNFT 6.9K
- Earning Date
- LOGC 03-03-2025
- GNFT 09-19-2024
- Dividend Yield
- LOGC N/A
- GNFT N/A
- EPS Growth
- LOGC N/A
- GNFT N/A
- EPS
- LOGC N/A
- GNFT 0.47
- Revenue
- LOGC $96,000,000.00
- GNFT $86,225,222.00
- Revenue This Year
- LOGC N/A
- GNFT $145.20
- Revenue Next Year
- LOGC $422.91
- GNFT N/A
- P/E Ratio
- LOGC N/A
- GNFT $7.56
- Revenue Growth
- LOGC N/A
- GNFT 175.45
- 52 Week Low
- LOGC $4.13
- GNFT $3.33
- 52 Week High
- LOGC $8.24
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- LOGC 49.11
- GNFT 31.89
- Support Level
- LOGC $6.29
- GNFT $3.35
- Resistance Level
- LOGC $7.42
- GNFT $3.57
- Average True Range (ATR)
- LOGC 0.32
- GNFT 0.11
- MACD
- LOGC -0.03
- GNFT 0.01
- Stochastic Oscillator
- LOGC 51.56
- GNFT 21.82
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.